Condition: Lung Cancer
Interventions: Drug: Sacituzumab Govitecan; Drug: Pembrolizumab
Sponsor: Chinese University of Hong Kong
Not yet recruiting
Interventions: Drug: Sacituzumab Govitecan; Drug: Pembrolizumab
Sponsor: Chinese University of Hong Kong
Not yet recruiting